Decreased fluid volume to reduce organ damage: a new approach to burn shock resuscitation? A preliminary study.
S Arlati, E Storti, V Pradella...
https://pubmed.ncbi.nlm.nih.gov/17137702Actively Recruiting
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-01-15
200
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying the outcomes of adults with severe burns covering more than 30% of their total body surface area. The study focuses on how albumin administration during the first 24 hours of burn resuscitation may impact prognosis, including risks like organ failure and mortality. This observational study aims to collect detailed data on patient outcomes to help design future interventional trials evaluating albumin's role in burn care. Participants are adults aged 18 to 80 years admitted to intensive care units within 12 hours of severe burns. The study observes current management practices, including how albumin is given, such as dose, duration, and method of administration. The research follows patients for 90 days after admission to track their health and treatments. During the study, researchers will monitor combined outcomes of death, severe acute kidney failure, and serious respiratory distress within 28 days after the burn injury. They will also assess rates of kidney failure, respiratory distress, abdominal complications, sepsis, and organ function scores up to 90 days post-injury. This thorough follow-up helps understand how albumin use relates to recovery and complications in severe burn patients.
CONDITIONS
Albumin and Prognosis of Severely Patients Burns
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - Up to 12 hours after burn injury
Participants are screened for eligibility to participate in the trial.
Duration - 90 days after admission
Participants with severe burns are observed and data are collected on their clinical status, including kidney function, respiratory status, and other complications.
Data collection at multiple time points, including Days 1 to 7, Day 28, and Day 90
Total: 1 location
1
Hopital saint Louis
Paris, France, France, 75010
Actively Recruiting
F
François Dr DEPRET, MD
M
Matthieu Pr LEGRAND, MD-PhD
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
S Arlati, E Storti, V Pradella...
https://pubmed.ncbi.nlm.nih.gov/17137702Stephanie A Mason, Avery B Nathens, Celeste C Finnerty...
https://pubmed.ncbi.nlm.nih.gov/27828823Sabri Soussi, Marina Taccori, Christian De Tymowski...
https://pubmed.ncbi.nlm.nih.gov/29561390Matthew B Klein, Douglas Hayden, Constance Elson...
https://pubmed.ncbi.nlm.nih.gov/17414612Katharine W Markell, Evan M Renz, Christopher E White...
https://pubmed.ncbi.nlm.nih.gov/19476867Andrew B Cooper, Stephen M Cohn, Haibo S Zhang...
https://pubmed.ncbi.nlm.nih.gov/16398734Amalia Cochran, Stephen E Morris, Linda S Edelman...
https://pubmed.ncbi.nlm.nih.gov/17223485